Tricyclic anti-allergy and use as anti-inflammatory agents

Claim 2

A compound having the structural formula I ##STR10## or pharmaceutically acceptable salts thereof, wherein A is ##STR11## B is independently oxygen or sulfur; R 1 -R 8 may be the same or different and are hydrogen or alkyl having from 1 to 6 carbon atoms and two adjacent R 1 -R 8 substituents may be combined to form an additional carbon to carbon bond; 1and m may be the same or different and are 0 or 1; the ring labeled, Q, may optionally contain up to two additional double bonds; n is 0, 1 and 2; W and X may be the same or different and are hydrogen, hydroxy, alkyl having from 1 to 6 carbon atoms, halogen, nitro, alkoxy having from 1 to 6 carbon atoms, tri-fluoromethyl, cyano, cycloalkyl having from 3 to 7 carbon atoms, alkenyloxy having from 3 to 6 carbon atoms, alkynyloxy having from 3 to 6 carbon atoms, S(O) p -R a {wherein p is 0, 1 or 2 and R a is alkyl having from 1 to 6 carbon atoms}, NHSO 2 R a {wherein R a is as defined herein}, NHSO 2 CF 3 , NHCOCF 3 , SO 2 NH 2 , COR b {wherein R b is OH, NH 2 or OR a (wherein R a is as defined herein)}, O-D-COR b {wherein D is alkylene having from 1 to 4 carbon atoms and R b is as defined herein}, or NHCOR c {wherein R c is hydrogen, alkyl having from 1 to 6 carbon atoms, alkoxy having from 1 to 6 carbon atoms, COR d (wherein R d is hydroxy or alkoxy having from 1 to 6 carbon atoms) or NHR e (wherein R e is hydrogen or alkyl having from 1 to 6 carbon atoms)}, or phenoxy {wherein the benzene ring may be substituted with any of the other substituents W and X}; Y and Z may be the same or different and are CH or N; V is phenyl, naphthyl, indenyl, indanyl, pyridyl, pyrimidinyl, thienyl, furyl or thiazolyl, any of which may be substituted with W and X as defined herein; R 9 and R 10 are independently hydrogen or alkyl having from 1 to 6 carbon atoms; and 2'-methyl-pyrano-5',6':3,4-(1-phenyl-2-2-oxo-1,2-dihydroquinoline) is excluded.

Claim 3

The compounds defined in claim 1 wherein n is 0.

Claim 4

The compounds defined in claim 2 wherein Y is CH.

Claim 5

The compounds defined in claim 3 having the structural formula: ##STR12##

Claim 6

The compounds defined in claim 4 wherein Z is N.

Claim 7

The compounds defined in claim 5 wherein l and m are each zero.

Claim 8

The compounds defined in claim 5 wherein l and m are 1.

Claim 9

The compounds defined in claim 6 or 7 wherein B is oxygen.

Claim 10

The compounds defined in claim 8 wherein V is ##STR13##

Claim 11

The compounds defined in claim 9 having the structural formula: ##STR14##

Claim 12

The compounds defined in claim 9 having the structural formula: ##STR15##

Claim 13

The compounds defined in claim 10 or 11 wherein R 1 -R 8 are hydrogen or methyl.

Claim 14

The compounds defined in claim 12 wherein zero or one of R 1 -R 8 is methyl and the rest are hydrogen.

Claim 15

The compounds defined in claim 13 wherein W is 3-chloro and X is hydrogen, chlorine or fluorine.

Claim 16

The compounds defined in claim 13 wherein W is 3-methoxy and X is hydrogen or fluorine.

Claim 17

The compounds defined in claim 13 wherein W and X are both hydrogen.

Claim 18

The compounds defined in claim 6 having the structural formula: ##STR16##

Claim 19

The compounds defined in claim 6 having the structural formula: ##STR17##

Claim 20

The compounds defined in claim 18 wherein W is 3-chloro and X is hydrogen, chlorine or fluorine.

Claim 21

The compounds defined in claim 18 wherein W is 3-methoxy and X is hydrogen or fluorine.

Claim 22

The compounds defined in claim 18 wherein W and X are both hydrogen.

Claim 23

The compounds defined in claim 1 having the names: 3,5-dihydro-5-phenyl-furo[3,2-c][1,8]naphthyridin-4[2H]-one; 6-phenyl-2,3,4,6-tetrahydro-pyrano[3,2-c][1,8]naphthyridin-5-one; 2-methyl-3,5-dihydro-5-phenyl-furo[3,2-c][1,8]naphthyridin-4[2H]-one; 3,9-dihydro-9-phenyl-furo[2,3-b][1,8]naphthyridin-4[2H]-one; 3,9-dihydro-9-(p-methylphenyl)-furo[2,3-b][1,8]naphthyridin-4[2H]-one; 3,9-dihydro-2-methyl-9-phenyl-furo[2,3-b][1,8]naphthyridin-4[2H]-one; 3,5-dihydro-5-(p-methylphenyl)-furo[3,2-c][1,8]naphthyridin-4[2H]-one; 3,5-dihydro-5-(p-fluorophenyl)-furo[3,2-c][1,8]naphthyridin-4[2H]-one; 3,5-Dihydro-5-(m-methoxyphenyl)-furo[3,2-c][1,8]naphthyridin-4[2H]-one; 3,5-Dihydro-5-(m-methylthiophenyl)-furo[3,2-c][1,8]naphthyridin-4[2H]-one; 3,9-dihydro-9-(p-fluorophenyl)-furo[2,3-b][1,8]naphthyridin-4[2H]-one; 3,9-dihydro-9-(m-methoxyphenyl)-furo[2,3-b][1,8]naphthyridin-4[2H]-one;

Claim 24

9-dihydro-9-(m-methylthiophenyl)-furo[3,2-c][1,8]naphthyridin-4[2H]-one;3,5-dihydro-5-(3,4dichlorophenyl)-furo[3,2-c][1,8]-naphthyridin-4[2H]-one; 3,5-dihydro-5-(3,4-dichlorophenyl)-2-methyl-furo [3,2-c][1,8]-naphthyridin-4[2H]-one; 3,5-dihydro-5-(4-chlorophenyl)-furo[3,2-c][1,8]naphthyridin-4[2H]-one; 3,5-dihydro-5-(3-chlorophenyl)-furo[3,2-c][1,8]naphthyridin-4[2H]-one; 3,5-dihydro-5-(3-chlorophenyl)-2-methyl-furo[3,2-c][1,8]naphthyridin-4[2H]-one; 3,5-dihydro-5-(4-fluorophenyl)-2-methy-furo[3,2-c][1,8]naphthyridin-4[2H]-one; 3,5-dihydro-5-(3-methoxyphenyl)-2-methyl-furo [3,2-c][1,8]-naphthyridin-4[2H]-one; 3,5-Dihydro-5-(3,5-dichlorophenyl)-furo[3,2-c][1,8]naphthyridin-4[2H]-one; 3,5-Dihydro-5-(3,5-dichlorophenyl)-2-methyl-furo [3,2-c][1,8]-naphthyridin-4[2H]-one; 3,5-Dihydro-5-phenyl-2,2-dimethyl-furo[3,2-c][1,8]naphthyridin-4[2H]-one; 3,5-Dihydro-5-(3-methysulfonylaminophenyl)-2-methylfuro[3,2-c][1,8]-naphthyridin-4[2H]-one; 3,5-dihydro-5-(3-methylsulfonylaminophenyl)-furo [3,2-c][1,8]-naphthyridin-4[2H]-one; 3,9-Dihydro-9-(3,4-dichlorophenyl)-furo[2,3-b][1,8]naphthyridin-4[2H]-one; 3,9-Dihydro-9-(4-chlorophenyl)-furo[2,3-b][1,8]-naphthyridin-4[2H]-one; 3,9-Dihydro-9-(3-chlorophenyl)-furo[2,3-b][1,8]-naphthyridin-4[2H]-one; 3,9-Dihydro-9-(3-chlorophenyl)-2-methyl-furo[2,3-b][1,8]-naphthyridin-4[2H]-one; 3,9-Dihydro-9-(4-fluorophenyl)-2-methyl-furo[2,3-b][1,8]-naphthyridin-4[2H]-one;

Claim 25

9-dihydro-9-(m-methylthiophenyl)-furo[3,2-c][1,8]naphthyridin-4[2H]-one;3,5-dihydro-5-(3,4dichlorophenyl)-furo[3,2-c][1,8]-naphthyridin-4[2H]-one; 3,5-dihydro-5-(3,4-dichlorophenyl)-2-methyl-furo [3,2-c][1,8]-naphthyridin-4[2H]-one; 3,5-dihydro-5-(4-chlorophenyl)-furo[3,2-c][1,8]naphthyridin-4[2H]-one; 3,5-dihydro-5-(3-chlorophenyl)-furo[3,2-c][1,8]naphthyridin-4[2H]-one; 3,5-dihydro-5-(3-chlorophenyl)-2-methyl-furo[3,2-c][1,8]naphthyridin-4[2H]-one; 3,5-dihydro-5-(4-fluorophenyl)-2-methy-furo[3,2-c][1,8]naphthyridin-4[2H]-one; 3,5-dihydro-5-(3-methoxyphenyl)-2-methyl-furo [3,2-c][1,8]-naphthyridin-4[2H]-one; 3,5-Dihydro-5-(3,5-dichlorophenyl)-furo[3,2-c][1,8]naphthyridin-4[2H]-one; 3,5-Dihydro-5-(3,5-dichlorophenyl)-2-methyl-furo [3,2-c][1,8]-naphthyridin-4[2H]-one; 3,5-Dihydro-5-phenyl-2,2-dimethyl-furo[3,2-c][1,8]naphthyridin-4[2H]-one; 3,5-Dihydro-5-(3-methysulfonylaminophenyl)-2-methylfuro[3,2-c][1,8]-naphthyridin-4[2H]-one; 3,5-dihydro-5-(3-methylsulfonylaminophenyl)-furo [3,2-c][1,8]-naphthyridin-4[2H]-one; 3,9-Dihydro-9-(3,4-dichlorophenyl)-furo[2,3-b][1,8]naphthyridin-4[2H]-one; 3,9-Dihydro-9-(4-chlorophenyl)-furo[2,3-b][1,8]-naphthyridin-4[2H]-one; 3,9-Dihydro-9-(3-chlorophenyl)-furo[2,3-b][1,8]-naphthyridin-4[2H]-one; 3,9-Dihydro-9-(3-chlorophenyl)-2-methyl-furo[2,3-b][1,8]-naphthyridin-4[2H]-one; 3,9-Dihydro-9-(4-fluorophenyl)-2-methyl-furo[2,3-b][1,8]-naphthyridin-4[2H]-one;

Claim 26

9-Dihydro-9-(3-methoxyphenyl)-2-methyl-furo [2,3-b][1,8]-naphthyridin-4[2H]-one; 3,9-Dihydro-9-(3,5-dichlorophenyl)-furo[2,3-b][1,8]naphthyridin-4[2H]-one; 3,9-Dihydro-9-(3,5-dichlorophenyl)-2-methyl-furo [2,3-b][1,8]-naphthyridin-4[2H]-one; 3,9-Dihydro-9-(3-methylsulfonylaminophenyl)-2-methylfuro[2,3-b][1,8]-naphthyridin-4[2H]-one; 6-(4-Chlorophenyl)-2,3,4,6-tetrahydro-5H-pyrano[3,2-c][1,8]naphthyridin-5-one; 6-(3,4-Dichlorophenyl)-2,3,4,6-tetrahydro-5H-pyrano [3,2-c][1,8]naphthyridin-5-one; 6-(4-Methoxyphenyl)-2,3,4,6-tetrahydro-5H-pyrano [3,2-c][1,8]naphthyridin-5-one; 6-(4-Methylphenyl)-2,3,4,6-tetrahydro-5H-pyrano [3,2-c][1,8]naphthyridin-5-one; 10-(3,4-Dichlorophenyl)-2,3,4,10-tetrahydro-5H-pyrano[2,3-b][1,8]naphthyridin-5-one; 10-(4-Methoxyphenyl)-2,3,4,10-tetrahydro-5H-pyrano[2,3-b][1,8]naphthyridin-5-one; 10-(4-Chlorophenyl)-2,3,4,10-tetrahydro-5H-pyrano2,3-b][1,8]naphthyridin-5-one; 10-(4-Methylphenyl)-2,3,4,10-tetrahydro-5H-pyrano-[2,3-b][1,8]naphthyridin-5-one; 10-Phenyl-2,3,4,10-tetrahydro-5H-pyrano-[2,3-b][1,8]naphthyridin-5-one; 7-Phenyl-3,4,5,7-tetrahydro-oxepino[3,2-c][1,8]naphthyridin-6[2H]-one; 7-(4-Chlorophenyl)-3,4,5,7-tetrahydro-oxepino[3,2-c][1,8]-naphthyridin-6[2H]-one; 7-(3-Chlorophenyl)-3,4,5,7-tetrahydro-oxepino[3,2-c][1,8]-naphthyridin-6[2H]-one; 7-(3-Methoxyphenyl)-3,4,5,7-tetrahydro-oxepino[3,2-c][ 1,8]-naphthyridin-6[2H]-one; 7-(3-Hydroxyphenyl)-3,4,5,7-tetrahydro-oxepino[3,2-c][1,8]-naphthyridin-6[2H]-one; and 3,5-Dihydro-5-phenyl-thieno[2,3-c][1,8]naphthyridin-4[2H]-one.

Claim 27

9-Dihydro-9-(3-methoxyphenyl)-2-methyl-furo [2,3-b][1,8]-naphthyridin-4[2H]-one; 3,9-Dihydro-9-(3,5-dichlorophenyl)-furo[2,3-b][1,8]naphthyridin-4[2H]-one; 3,9-Dihydro-9-(3,5-dichlorophenyl)-2-methyl-furo [2,3-b][1,8]-naphthyridin-4[2H]-one; 3,9-Dihydro-9-(3-methylsulfonylaminophenyl)-2-methylfuro[2,3-b][1,8]-naphthyridin-4[2H]-one; 6-(4-Chlorophenyl)-2,3,4,6-tetrahydro-5H-pyrano[3,2-c][1,8]naphthyridin-5-one; 6-(3,4-Dichlorophenyl)-2,3,4,6-tetrahydro-5H-pyrano [3,2-c][1,8]naphthyridin-5-one; 6-(4-Methoxyphenyl)-2,3,4,6-tetrahydro-5H-pyrano [3,2-c][1,8]naphthyridin-5-one; 6-(4-Methylphenyl)-2,3,4,6-tetrahydro-5H-pyrano [3,2-c][1,8]naphthyridin-5-one; 10-(3,4-Dichlorophenyl)-2,3,4,10-tetrahydro-5H-pyrano[2,3-b][1,8]naphthyridin-5-one; 10-(4-Methoxyphenyl)-2,3,4,10-tetrahydro-5H-pyrano[2,3-b][1,8]naphthyridin-5-one; 10-(4-Chlorophenyl)-2,3,4,10-tetrahydro-5H-pyrano2,3-b][1,8]naphthyridin-5-one; 10-(4-Methylphenyl)-2,3,4,10-tetrahydro-5H-pyrano-[2,3-b][1,8]naphthyridin-5-one; 10-Phenyl-2,3,4,10-tetrahydro-5H-pyrano-[2,3-b][1,8]naphthyridin-5-one; 7-Phenyl-3,4,5,7-tetrahydro-oxepino[3,2-c][1,8]naphthyridin-6[2H]-one; 7-(4-Chlorophenyl)-3,4,5,7-tetrahydro-oxepino[3,2-c][1,8]-naphthyridin-6[2H]-one; 7-(3-Chlorophenyl)-3,4,5,7-tetrahydro-oxepino[3,2-c][1,8]-naphthyridin-6[2H]-one; 7-(3-Methoxyphenyl)-3,4,5,7-tetrahydro-oxepino[3,2-c][ 1,8]-naphthyridin-6[2H]-one; 7-(3-Hydroxyphenyl)-3,4,5,7-tetrahydro-oxepino[3,2-c][1,8]-naphthyridin-6[2H]-one; and 3,5-Dihydro-5-phenyl-thieno[2,3-c][1,8]naphthyridin-4[2H]-one.

Claim 28

A pharmaceutical composition for treating allergic reactions which comprises a compound having the structural formula I ##STR18## or pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable carrier, wherein A is ##STR19## B is independently oxygen or sulfur; R 1 -R 8 may be the same or different and are hydrogen or alkyl having from 1 to 6 carbon atoms and two adjacent R 1 -R 8 substituents may be combined to form an additional carbon to carbon bond; 1and m may be the same or different and are 0 or one; the ring labeled, Q, may optionally contain up to two additional double bonds; n is 0, 1 and 2; W and X may be the same or different and are hydrogen, hydroxy, alkyl having from 1 to 6 carbon atoms, halogen, nitro, alkoxy having from 1 to 6 carbon atoms, tri-fluoromethyl, cyano, cycloalkyl having from 3 to 7 carbon atoms, alkenyloxy having from 3 to 6 carbon atoms, alkynylocy having from 3 to 6 carbon atoms, S(O) p -R a {wherein p is 0, 1 or 2 and R a is alkyl having from 1 to 6 carbon atoms}, NHSO 2 R a {wherein R a is as defined herein}, NHSO 2 CF 3 , NHCOCF 3 , SO 2 NH 2 , COR b {wherein R b is OH, NH 2 or OR a (wherein R a is as defined herein)}, O-D-COR b {wherein D is alkylene having from 1 to 4 carbon atoms and R b is as defined herein}, NHCOR c {wherein R c is hydrogen, alkyl having from 1 to 6 carbon atoms, alkoxy having from 1 to 6 carbon atoms, COR d (wherein R d is hydroxy or alkoxy having from 1 to 6 carbon atoms) or NHR e (wherein R e is hydrogen or alkyl having from 1 to 6 carbon atoms)}, or phenoxy {wherein the benzene ring may be substituted with any of the other substitutents W and X}; Y and Z may be the same or different and are CH or N; V is phenyl, naphthyl, indenyl, indanyl, pyridyl, pyrimidinyl, thienyl, furyl or thiazolyl, any of which may be substituted with W and X as defined herein; and R 9 and R 10 are independently hydrogen or alkyl having from 1 to 6 carbon atoms.

Claim 29

A pharmaceutical composition for treating allergic reactions which comprises a compound having the structural formula I ##STR18## or pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable carrier, wherein A is ##STR19## B is independently oxygen or sulfur; R 1 -R 8 may be the same or different and are hydrogen or alkyl having from 1 to 6 carbon atoms and two adjacent R 1 -R 8 substituents may be combined to form an additional carbon to carbon bond; 1and m may be the same or different and are 0 or one; the ring labeled, Q, may optionally contain up to two additional double bonds; n is 0, 1 and 2; W and X may be the same or different and are hydrogen, hydroxy, alkyl having from 1 to 6 carbon atoms, halogen, nitro, alkoxy having from 1 to 6 carbon atoms, tri-fluoromethyl, cyano, cycloalkyl having from 3 to 7 carbon atoms, alkenyloxy having from 3 to 6 carbon atoms, alkynylocy having from 3 to 6 carbon atoms, S(O) p -R a {wherein p is 0, 1 or 2 and R a is alkyl having from 1 to 6 carbon atoms}, NHSO 2 R a {wherein R a is as defined herein}, NHSO 2 CF 3 , NHCOCF 3 , SO 2 NH 2 , COR b {wherein R b is OH, NH 2 or OR a (wherein R a is as defined herein)}, O-D-COR b {wherein D is alkylene having from 1 to 4 carbon atoms and R b is as defined herein}, NHCOR c {wherein R c is hydrogen, alkyl having from 1 to 6 carbon atoms, alkoxy having from 1 to 6 carbon atoms, COR d (wherein R d is hydroxy or alkoxy having from 1 to 6 carbon atoms) or NHR e (wherein R e is hydrogen or alkyl having from 1 to 6 carbon atoms)}, or phenoxy {wherein the benzene ring may be substituted with any of the other substitutents W and X}; Y and Z may be the same or different and are CH or N; V is phenyl, naphthyl, indenyl, indanyl, pyridyl, pyrimidinyl, thienyl, furyl or thiazolyl, any of which may be substituted with W and X as defined herein; and R 9 and R 10 are independently hydrogen or alkyl having from 1 to 6 carbon atoms.

Claim 30

A pharmaceutical composition for treating inflammation which comprises a compound having the structural formula I ##STR20## or pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable carrier, wherein A is ##STR21## B is independently oxygen or sulfur; R 1 -R 8 may be the same or different and are hydrogen or alkyl having from 1 to 6 carbon atoms and two adjacent R 1 -R 8 substituents may be combined to form an additional carbon to carbon bond; l and m may be the same or different and are 0 or one; the ring labeled, Q, may optionally contain up to two additional double bonds; n is 0, 1 or 2; W and X may be the same or different and are hydrogen, hydroxy, alkyl having from 1 to 6 carbon atoms, halogen, nitro, alkoxy having from 1 to 6 carbon atoms, tri-fluoromethyl, cyano, cycloalkyl having from 3 to 7 carbon atoms, alkenyloxy having from 3 to 6 carbon atoms, alkynyloxy having from 3 to 6 carbon atoms, S(O) p -R a {wherein P is 0, 1 or 2 and R a is alkyl having from 1 to 6 carbon atoms}, NHSO 2 R a {wherein R a is as defined herein}, NHSO 2 CF 3 , NHCOCF 3 , SO 2 NH 2 , COR b {wherein R b is OH, NH 2 or OR a (wherein R a is as defined herein)}, O-D-COR b {wherein D is alkylene having from 1 to 4 carbon atoms and R b is as defined herein}, NHCOR c {wherein R c is hydrogen, alkyl having from 1 to 6 carbon atoms, alkoxy having from 1 to 6 carbon atoms, COR d (wherein R d is hydroxy or alkoxy having from 1 to 6 carbon atoms) or NHR e (wherein R e is hydrogen or alkyl having from 1 to 6 carbon atoms)}, or phenoxy {wherein the benzene ring may be substituted with any of the other substituents W and X}; Y and Z may be the same or different and are CH or N; V is phenyl, naphthyl, indenyl, indanyl, pyridyl, pyrimidinyl, thienyl, furyl or thiazolyl, any of which may be substituted with W and X as defined herein; and R 9 and R 10 are independently hydrogen or alkyl having from 1 to 6 carbon atoms.

Claim 31

A pharmaceutical composition for treating inflammation which comprises a compound having the structural formula I ##STR20## or pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable carrier, wherein A is ##STR21## B is independently oxygen or sulfur; R 1 -R 8 may be the same or different and are hydrogen or alkyl having from 1 to 6 carbon atoms and two adjacent R 1 -R 8 substituents may be combined to form an additional carbon to carbon bond; l and m may be the same or different and are 0 or one; the ring labeled, Q, may optionally contain up to two additional double bonds; n is 0, 1 or 2; W and X may be the same or different and are hydrogen, hydroxy, alkyl having from 1 to 6 carbon atoms, halogen, nitro, alkoxy having from 1 to 6 carbon atoms, tri-fluoromethyl, cyano, cycloalkyl having from 3 to 7 carbon atoms, alkenyloxy having from 3 to 6 carbon atoms, alkynyloxy having from 3 to 6 carbon atoms, S(O) p -R a {wherein P is 0, 1 or 2 and R a is alkyl having from 1 to 6 carbon atoms}, NHSO 2 R a {wherein R a is as defined herein}, NHSO 2 CF 3 , NHCOCF 3 , SO 2 NH 2 , COR b {wherein R b is OH, NH 2 or OR a (wherein R a is as defined herein)}, O-D-COR b {wherein D is alkylene having from 1 to 4 carbon atoms and R b is as defined herein}, NHCOR c {wherein R c is hydrogen, alkyl having from 1 to 6 carbon atoms, alkoxy having from 1 to 6 carbon atoms, COR d (wherein R d is hydroxy or alkoxy having from 1 to 6 carbon atoms) or NHR e (wherein R e is hydrogen or alkyl having from 1 to 6 carbon atoms)}, or phenoxy {wherein the benzene ring may be substituted with any of the other substituents W and X}; Y and Z may be the same or different and are CH or N; V is phenyl, naphthyl, indenyl, indanyl, pyridyl, pyrimidinyl, thienyl, furyl or thiazolyl, any of which may be substituted with W and X as defined herein; and R 9 and R 10 are independently hydrogen or alkyl having from 1 to 6 carbon atoms.

Claim 32

A pharmaceutically composition for treating peptic ulcers which comprises a compound having the structural formula I ##STR22## or pharmaceutically acceptable salts thereof, in combination with pharmaceutically acceptable carrier, wherein A is ##STR23## B is independently oxygen or sulfur; R 1 -R 8 may be the same or different and are hydrogen or alkyl having from 1 to 6 carbon atoms and two adjacent R 1 -R 8 substituents may be combined to form an additional carbon to carbon bond; l and m may be the same or different and are 0 or one; the ring labeled, Q, may optionally contain up to two additional double bonds; n is 0, 1 and 2; W and X may be the same or different and are hydrogen, hydroxy, alkyl having from 1 to 6 carbon atoms halogen, nitro, alkoxy, having from 1 to 6 carbon atoms, tri-fluoromethyl, cyano, cycloalkyl having from 3 to 7 carbon atoms, alkenyloxy having from 3 to 6 carbon atoms, alkynyloxy having from 3 to 6 carbon atoms, S(O) p -R a {wherein p is 0, 1 or 2 and R a is alkyl having from 1 to 6 carbon atoms}, NHSO 2 R a {wherein R a is as defined herein}, NHSO 2 CF 3 , NHCOCF 3 , SO 2 NH 2 , COR b {wherein R b is OH, NH 2 or OR a (wherein R a is as defined herein)}, O-D-COR b {wherein D is alkylene having from 1 to 4 carbon atoms and R b is as defined herein}, NHCOR c {wherein R c is hydrogen, alkyl having from 1 to 6 carbon atoms, alkoxy having from 1 to 6 carbon atoms, COR d (wherein R d is hydroxy or alkoxy having from 1 to 6 carbon atoms) or NHR e (wherein R e is hydrogen or alkyl having from 1 to 6 carbon atoms)}, or phenoxy {wherein the benzene ring may be substituted with any of the other substituents W and X}; Y and Z may be the same or different and are CH or N; V is phenyl, naphthyl, indenyl, indanyl, pyridyl, pyrimidinyl, thienyl, furyl or thiazolyl, any of which may be substituted with W and X as defined herein; and R 9 and R 10 are independently hydrogen or alkyl having from 1 to 6 carbon atoms.

Claim 33

A pharmaceutically composition for treating peptic ulcers which comprises a compound having the structural formula I ##STR22## or pharmaceutically acceptable salts thereof, in combination with pharmaceutically acceptable carrier, wherein A is ##STR23## B is independently oxygen or sulfur; R 1 -R 8 may be the same or different and are hydrogen or alkyl having from 1 to 6 carbon atoms and two adjacent R 1 -R 8 substituents may be combined to form an additional carbon to carbon bond; l and m may be the same or different and are 0 or one; the ring labeled, Q, may optionally contain up to two additional double bonds; n is 0, 1 and 2; W and X may be the same or different and are hydrogen, hydroxy, alkyl having from 1 to 6 carbon atoms halogen, nitro, alkoxy, having from 1 to 6 carbon atoms, tri-fluoromethyl, cyano, cycloalkyl having from 3 to 7 carbon atoms, alkenyloxy having from 3 to 6 carbon atoms, alkynyloxy having from 3 to 6 carbon atoms, S(O) p -R a {wherein p is 0, 1 or 2 and R a is alkyl having from 1 to 6 carbon atoms}, NHSO 2 R a {wherein R a is as defined herein}, NHSO 2 CF 3 , NHCOCF 3 , SO 2 NH 2 , COR b {wherein R b is OH, NH 2 or OR a (wherein R a is as defined herein)}, O-D-COR b {wherein D is alkylene having from 1 to 4 carbon atoms and R b is as defined herein}, NHCOR c {wherein R c is hydrogen, alkyl having from 1 to 6 carbon atoms, alkoxy having from 1 to 6 carbon atoms, COR d (wherein R d is hydroxy or alkoxy having from 1 to 6 carbon atoms) or NHR e (wherein R e is hydrogen or alkyl having from 1 to 6 carbon atoms)}, or phenoxy {wherein the benzene ring may be substituted with any of the other substituents W and X}; Y and Z may be the same or different and are CH or N; V is phenyl, naphthyl, indenyl, indanyl, pyridyl, pyrimidinyl, thienyl, furyl or thiazolyl, any of which may be substituted with W and X as defined herein; and R 9 and R 10 are independently hydrogen or alkyl having from 1 to 6 carbon atoms.

Claim 34

A pharmaceutical composition according to claim 23 which comprises a compound having structural formula ##STR24## or pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable carrier, wherein: A is ##STR25## B is independently oxygen or sulfur; R 1 -R 6 may be the same or different and are hydrogen or alkyl having from 1 to 6 carbon atoms; m is 0 or 1, provided that, when m is 0, R 2 and R 4 may be joined to form a carbon to carbon bond; n is 0, 1 and 2; W and X may be the same or different and are hydrogen, alkyl having from 1 to 6 carbon atoms, alkoxy having from 1 to 6 carbon atoms, halogen, trifloromethyl, nitro, cyano, carboxy, hydroxy, alkenyloxy having from 3 to 8 carbon atoms, alkynyloxy having from 3 to 8 carbon atoms, cycloalkyl having from 4 to 8 carbon atoms, S(O) p -R a {wherein p is 0, 1 or 2 and R a is alkyl having from 1 to 6 carbon atoms}, or phenoxy {wherein the benzene ring may be substiuted with any of the other substituents W and X}; Y and Z may be the same or different and are CH or N; V is phenyl, naphthyl, indenyl, indanyl, pyridyl, pyrimidinyl, thienyl, furyl or thiazolyl, any of which may be substituted with W and X as defined herein; and R 9 is independently hydrogen or alkyl having from 1 to 6 carbon atoms.

Claim 35

A pharmaceutical composition according to claim 24 which comprises a compound having structural formula ##STR26## or pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable carrier, wherein: A is ##STR27## B is independently oxygen or sulfur; R 1 -R 6 may be the same or different and are hydrogen or alkyl having from 1 to 6 carbon atoms; m is 0 or 1, provided that, when m is 0, R 2 and R 4 may be joined to form a carbon to carbon bond; n is 0, 1 and 2; W and X may be the same or different and are hydrogen, alkyl having from 1 to 6 carbon atoms, alkoxy having from 1 to 6 carbon atoms, halogen, trifluoromethyl, nitro, cyano, carboxy, hydroxy, alkenyloxy having from 3 to 8 carbon atoms, alkynyloxy having from 3 to 8 carbon atoms, cycloalkyl having from 4 to 8 carbon atoms, S(O) p -R a {wherein p is 0, 1 or 2 and R a is alkyl having from 1 to 6 carbon atoms}, or phenoxy {wherein the benzene ring may be substituted with any of the other substituents W and X}; Y and Z may be the same or different and are CH or N; V is phenyl, naphthyl, indenyl, indanyl, pyridyl, pyrimidinyl, thienyl, furyl or thiazolyl, any of which may be substituted with W and X as defined herein; and R 9 is independently hydrogen or alkyl having from 1 to 6 carbon atoms.

Claim 36

A pharmaceutical composition according to claim 25 which comprises a compound having structural formula ##STR28## or pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable carrier, wherein: A is ##STR29## B is independently oxygen or sulfur; R 1 -R 6 may be the same or different and are hydrogen or alkyl having from 1 to 6 carbon atoms; m is 0 or 1, provided that, when m is 0, R 2 and R 4 may be joined to form a carbon to carbon bond; n is 0, 1 and 2; W and X may be the same or different and are hydrogen, alkyl having from 1 to 6 carbon atoms, alkoxy having from 1 to 6 carbon atoms, halogen, trifluoromethyl, nitro, cyano, carboxy, hydroxy, alkenyloxy having from 3 to 8 carbon atoms, alkynloxy having from 3 to 8 carbon atoms, cycloalkyl having from 4 to 8 carbon atoms, S(O) p -R a {wherein p is 0, 1 or 2 and R a is alkyl having from 1 to 6 carbon atoms}, or phenoxy {wherein the benzene ring may be substituted with any of the other substituents W and X}; Y and Z may be the same or different and are CH or N; V is phenyl, naphthyl, indenyl, indanyl, pyridyl, pyrimidinyl, thienyl, furyl or thiazolyl, any of which may be substituted with W and X as defined herein; and R 9 is independently hydrogen or alkyl having from 1 to 6 carbon atoms.

Claim 37

A compound according to claim 1 having the name 3,5-dihydro-5-phenyl-furo[3,2-c][1,8]naphthyridin-4[2H]-one.

Claim 38

A compound according to claim 1 having the name 2-methyl-3,5-dihydro-5-phenyl-furo[3,2-c][1,8]naphthyridin-4[2H-one.

Claim 39

A compound according to claim 1 having the name 3,9-dihydro-9-phenyl-furo[2,3-b][1,8]naphthyridin-4[2H]-one.

Claim 40

A compound according to claim 1 having the name 3,9-dihydor-2 -methyl-9-phenyl-furo[2,3-b][1,8]naphthyridin-4[2H]-one.

Claim 41

A compound according to claim 1 having the name 3,5-dihydro-5-(p-fluorophenyl)-furo[3,2-c][1,8]naphthyridin-4[2H]-one.

Claim 42

A compound according to claim 1 having the name 3,5-dihydro-5-(3-chlorophenyl)-furo[3,2-c][1,8]naphthyridin-4[2H]-one.

Claim 43

A compound according to claim 1 having the name 3,9-dihydro-9-(3-chlorophenyl)-2-methyl-furo[2,3-b][1,8]-naphthyridin-4[2H]-one.

Claim 44

A compound according to claim 1 having the name, 3,9-dihyro-9-(4-fluorophenyl)-2-methyl-furo[2,3-b][1,8]-naphthyridin-4[2H]-one.

Claim 45

A compound according to claim 1 having the name 7-phenyl-3,4,5,7-tetrahydro-oxepino[3,2-c][1,8]naphthyridin-6[2H]-one.

Claim 46

A compound according to claim 1 having the name 7-(3-chlorophenyl)-3,4,5,7-tetrahydro-oxepino[3,2-c][1,8]-naphthyridin-6[2H-one.

Claim 47

A method for treating allergic reactions in a mammal which comprises administering an anti-allergic effective amount of the pharmaceutical composition defined in claim 23 to said mammal.

Claim 48

A method for treating inflammation in a mammal which comprises administering an anti-inflammatory effective amount of the pharmaceutical composition defined in claim 24 to said mammal.

Claim 49

A method for treating peptic ulcers in a mammal which comprises administering a cytoprotective effective amount of the pharmaceutical composition defined in claim 25 to said mammal.

Claim 50

A compound having the structural formula ##STR30## or pharmaceutically acceptable salts thereof, wherein: A is ##STR31## B is independently oxygen or sulfur; R 1 -R 6 may be the same or different and are hydrogen or alkyl having from 1 to 6 carbon atoms; m is 0 or 1, provided that, when m is 0, R 2 and R 4 may be joined to form a carbon to carbon bond; n is 0, 1 or 2; W and X may be the same or different and are hydrogen, alkyl having from 1 to 6 carbon atoms, alkoxy having from 1 to 6 carbon atoms, halogen, trifluoromethyl, nitro, cyano, carboxy, hydroxy, alkenyloxy having from 3 to 8 carbon atoms, alkynyloxy having from 3 to 8 carbon atoms, cycloalkyl having from 4 to 8 carbon atoms, S(O) p -R a {wherein p is 0, 1 or 2 and R a is alkyl having from 1 to 6 carbon atoms} or phenoxy {wherein the penzene ring may be substituted with any of the other substituents W and X}; Y an Z may be the same or different and are CH or N; V is phenyl, naphthyl, indenyl, indanyl, pyridyl, pyrimidinyl, thienyl, furyl or thiazolyl, any of which may be substituted with W and X as defined herein; R 9 is independently hydrogen or alkyl having from 1 to 6 carbon atoms; and 2'-methyl-pyrano-5',6':3,4-(1-phenyl-2-oxo-1,2-dihydroquinoline) is excluded.

Claim 51

A compound having the structural formula ##STR30## or pharmaceutically acceptable salts thereof, wherein: A is ##STR31## B is independently oxygen or sulfur; R 1 -R 6 may be the same or different and are hydrogen or alkyl having from 1 to 6 carbon atoms; m is 0 or 1, provided that, when m is 0, R 2 and R 4 may be joined to form a carbon to carbon bond; n is 0, 1 or 2; W and X may be the same or different and are hydrogen, alkyl having from 1 to 6 carbon atoms, alkoxy having from 1 to 6 carbon atoms, halogen, trifluoromethyl, nitro, cyano, carboxy, hydroxy, alkenyloxy having from 3 to 8 carbon atoms, alkynyloxy having from 3 to 8 carbon atoms, cycloalkyl having from 4 to 8 carbon atoms, S(O) p -R a {wherein p is 0, 1 or 2 and R a is alkyl having from 1 to 6 carbon atoms} or phenoxy {wherein the penzene ring may be substituted with any of the other substituents W and X}; Y an Z may be the same or different and are CH or N; V is phenyl, naphthyl, indenyl, indanyl, pyridyl, pyrimidinyl, thienyl, furyl or thiazolyl, any of which may be substituted with W and X as defined herein; R 9 is independently hydrogen or alkyl having from 1 to 6 carbon atoms; and 2'-methyl-pyrano-5',6':3,4-(1-phenyl-2-oxo-1,2-dihydroquinoline) is excluded.

Claim 52

The compounds defined in claim 42 having the name: 3,5-dihydro-5-phenyl-furo[3,2-c][1,8]naphthyridin-4[2H]-one; 6-phenyl-2,3,4,6-tetrahydro-pyrano[3,2-c][1,8]naphthyridin-5-one; 2-methyl-3,5-dihydro-5-phenyl-furo[3,2-c][1,8]naphthyridin-4[2H]-one; 3,9-dihydro-9-phenyl-furo[2,3-b][1,8]naphthyridin-4[2H]-one; 3,9-dihydro-9-(4-methylphenyl)-furo[2,3-b][1,8]naphthyridin-4[2H]-one; 3,9-dihydro-2-methyl-9-phenyl-furo[2,3-b][1,8]naphthyridin-4[2H]-one; 3,5-dihydro-5-(p-methylphenyl)-furo[3,2-c][1,8]naphthyridin-4[2H]-one; 3,5-dihydro-5-(p-fluorophenyl)-furo[3,2-c][1,8]naphthyridin-4[2H]-one; 3,5-dihydro-5-(m-methoxyphenyl)-furo[3,2-c][1,8]naphthyridin-4[2H]-one; 3,5-dihydro-5-(m-methylthiophenyl)-furo[3,2-c][1,8]naphthyridin-4[2H]-one;

Claim 53

9-dihydro-9-(p-fluorophenyl)-furo[2,3-b][1,8]naphthyridin-4[2H]-one; 3,9-dihyro-9-(m-methoxyphenyl)-furo[2,3-b][1,8]naphthyridin-4[2H]-one: or 3,9-dihydro-9-(m-methylthiophenyl)-furo[3,2-c][1,8]naphthyridin-4[2H]-one.

Claim 54

9-dihydro-9-(p-fluorophenyl)-furo[2,3-b][1,8]naphthyridin-4[2H]-one; 3,9-dihyro-9-(m-methoxyphenyl)-furo[2,3-b][1,8]naphthyridin-4[2H]-one: or 3,9-dihydro-9-(m-methylthiophenyl)-furo[3,2-c][1,8]naphthyridin-4[2H]-one.

Claim 55

A method for treating allergic reactions in a mammal which comprises administering an anti-allergic effective amount of the pharmaceutical composition defined in claim 26 to said mammal.

Claim 56

A method for treating inflammation in a mammal which comprises administering an anti-inflammatory effective amount of the pharmaceutical composition defined in claim 27 to said mammal.

Claim 57

A method for treating peptic ulcers in a mammal which comprises administering a cytoprotective effective amount of the pharmaceutical composition defined in claim 28 to said mammal.

Claim 58

The compounds defined in claim 5 wherein the sum of l and m equals one.